Physician profile
Patrick Lam
NPI 1326095613
$5,452.12
in general payments reported to CMS, 2019-2025
27 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $230 · 2021: $51.33 · 2022: $20.92 · 2023: $1,584 · 2024: $2,119 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,104.47 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $807.36 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Regeneron Healthcare Solutions, INC. | $550.37 | 2023-2025 | Dupixent |
| Genzyme Corporation | $522.60 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.72 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $403.91 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $258.08 | 2019-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $232.90 | 2024-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $225.87 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $124.76 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $114.45 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $105.97 | 2023-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $69.05 | 2024 | Givlaari |
| Pfizer INC. | $65.83 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $63.30 | 2019-2023 | Rebyota |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $51.61 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $50.71 | 2024 | Dificid, Pifeltro |
| Braintree Laboratories, INC. | $43.80 | 2023-2024 | Sutab, Suflave |
| Redhill Biopharma INC. | $36.81 | 2020-2023 | Talicia |
| Digestive Care, INC. | $35.58 | 2024 | Pertzye |
| Shionogi INC | $31.69 | 2019 | |
| Madrigal Pharmaceuticals | $27.80 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $24.74 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $22.31 | 2024 | |
| Lucid Diagnostics INC. | $20.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.67 | 2023 | Cyltezo |
| Shire North American Group INC | $17.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.